Search Results

Dealing with cancer.

Subjects: *PHARMACEUTICAL industry; *MERGERS & acquisitions; ANTIBODY-drug conjugates

• Source: Economist. 9/23/2023, Vol. 448 Issue 9364, p57-58. 2p.

Record details

Piramal Pharma Solutions announces opening of expanded ADC.

Subjects: ANTIBODY-drug conjugatesSCOTLANDPIRAMAL Pharma Solutions Inc.

• Source: FRPT- Chemical Snapshot. 1/8/2024, p23-24. 2p.

Record details

Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression

• Authors : Tozbikian, Gary; Krishnamurthy, Savitri; Bui, Marilyn M.

• Source: Archives of Pathology & Laboratory Medicine. February, 2024, Vol. 148 Issue 2, p242, 14 p.

Record details

Pfizer to Close $43 Billion Seagen Acquisition After FTC Nod.

• Authors : Cattan, Nacha (AUTHOR)

Subjects: ANTIBODY-drug conjugates; CANCER treatment; PANDEMICSPFIZER Inc. 001326495 PFIZER Inc. PFIZER Inc. 001326495 001326495 PFIZER Inc. 001326495 PFE; UNITED States. Federal Trade Commission. Bureau of Consumer Protection

• Source: Bloomberg.com. 12/12/2023, pN.PAG-N.PAG. 1p.

Record details

Bristol to Pay SystImmune Up to $8.4 Billion in Cancer-Drug Deal.

• Authors : Cattan, Nacha (AUTHOR)

Subjects: *CONTRACTS; ANTIBODY-drug conjugates; LUNG cancerCHINA

• Source: Bloomberg.com. 12/11/2023, pN.PAG-N.PAG. 1p.

Record details

AbbVie to Pay $10.1 Billion for Cancer-Drug Maker ImmunoGen.

• Authors : Smith, Gerry (AUTHOR)

Subjects: ANTIBODY-drug conjugates; DRUG accessibility; DRUG marketing

• Source: Bloomberg.com. 11/30/2023, pN.PAG-N.PAG. 1p.

Record details

AbbVie to Pay $10.1 Billion for Cancer-Drug Maker ImmunoGen.

• Authors : Lauerman, John (AUTHOR)

Subjects: *MERGERS & acquisitions; *PHARMACEUTICAL industry; ANTIBODY-drug conjugates

• Source: Bloomberg.com. 11/30/2023, pN.PAG-N.PAG. 1p.

Record details

Phase 1 Study of the Tissue Factor–Targeting Antibody-Drug Conjugate XB002 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and Neck.

• Authors : Ulahannan, S.¹ (AUTHOR); Johnson, M.² (AUTHOR); Weiss, M.³ (AUTHOR)

Subjects: *ANTIBODY-drug conjugates; *SQUAMOUS cell carcinoma; *IMMUNE checkpoint inhibitors

• Source: International Journal of Radiation Oncology, Biology, Physics. Apr2024, Vol. 118 Issue 5, pe31-e32. 2p.

Record details

A0539 - Preclinical evidence for the use of anti-TROP-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.

• Authors : Weiten, R. (AUTHOR); Niemann, M. (AUTHOR); Below, E. (AUTHOR)

Subjects: *CASTRATION-resistant prostate cancer; *ANTIBODY-drug conjugates

• Source: European Urology. 2024 Supplement 1, Vol. 85, pS1430-S1431. 2p.

Record details

Antibody–drug conjugates in acute myeloid leukaemia: more research needed.

• Authors : Kayser, Sabine^1,2 (AUTHOR)

Subjects: *ACUTE myeloid leukemia; *ANTIBODY-drug conjugates

• Source: Lancet Oncology. Mar2024, Vol. 25 Issue 3, p272-273. 2p.

Record details